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Abstract: Olfactory deﬁcits and executive dysfunction are
early and common symptoms in Parkinson’s disease (PD).
Previous studies have shown that hyposmia can be a ﬁrst
sign of PD. The aim of the present study was to determine
which of three olfactory tests and two selected tests of execu-
tive function would be the best predictor of future PD over
a 5 year period. In a cohort of 361 nonparkinsonian, non-
demented ﬁrst-degree relatives of PD patients, in whom
alternative causes of olfactory dysfunction were excluded, we
measured baseline performance on three olfactory and two
executive function tasks. Five years from baseline, clinical
neurological evaluation and/or a screening questionnaire,
sensitive to the presence of Parkinsonism, were used to
detect individuals developing clinical PD. Our results
show that in ﬁrst degree relatives of PD patients worse per-
formance on each of three olfactory processing tasks was
associated with an increased risk of developing PD within
5 years, whereas performance on selected tests of executive
dysfunction was not associated with an increased risk of
developing PD. Interestingly, impaired odor discrimination
was the best predictor for future PD.  2009 Movement
Disorder Society
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Olfactory loss is common in PD patients, with a
reported prevalence of up to 80 to 90%.1,2 The olfac-
tory deﬁcit in PD occurs even in early stage, untreated
PD patients and includes impairments in several
modalities, i.e., odor detection, discrimination and
identiﬁcation.3,4 In a cohort of ﬁrst degree relatives of
PD patients, we were able to demonstrate that unex-
plained hyposmia can be a ﬁrst sign of PD.5,6 These
ﬁndings were later conﬁrmed by an independent study
in a population of individuals with idiopathic hypo-
smia.7,8 Also, in a population-based study, hyposmia
was recently found to be associated with an increased
risk of future PD.9
The sense of smell can by dissected into at least
three different components.10 Odor detection testing
measures the lowest concentration of an odorant that
can be perceived by a subject. Odor identiﬁcation test-
ing involves the perception and naming of an odor pre-
sented. An odor discrimination task measures the abil-
ity to differentiate between a set of odorants. So far,
the predictive value of olfactory testing for a later di-
agnosis of PD has not been compared between tests of
different olfactory modalities, such as odor discrimina-
tion and odor identiﬁcation.
Early-stage cognitive disturbances in PD include ex-
ecutive dysfunction, visuo-spatial impairments, and dis-
turbances of working memory.11 Motor perseveration
and a decrease in sequential visuo-spatial memory
span, most likely reﬂecting executive dysfunction,
appear to be very early features of PD.12–14 In the
MPTP-treated primate, an animal model of PD, execu-
tive deﬁcits have been found before the appearance of
clinical motor disturbances,15 suggesting that these
impairments may be a feature of the pre-motor stages
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of PD. Indeed, in ﬁrst-degree relatives of PD patients
the incidence of PD-like executive dysfunction is
increased, possibly as a manifestation of pre-motor
PD.16 However, the predictive value of executive dys-
function for the future development of PD has never
been assessed prospectively.
The aim of the present study was to determine the
association between the risk of developing clinical PD
over a ﬁve-year period and baseline performance on
tests of olfactory and executive function as part of an
ongoing prospective cohort study in ﬁrst degree rela-
tives of PD patients. A further purpose of this study
was to determine which of the individual olfactory or
executive function subtests would be associated with
the highest risk of future PD.
SUBJECTS AND METHODS
Study Population/Subjects
At baseline, the study population consisted of 361
ﬁrst-degree relatives (285 children, 73 siblings, and 3
parents) of patients with sporadic PD. Subjects were
recruited partly from the general population and partly
from family members of patients at the outpatient
clinic for movement disorders of the VU University
Medical Center (VUMC).
As described previously,5 relatives were included
when they fulﬁlled the following criteria: (1) clinical
diagnosis of PD in the affected relative made by a
VUMC neurologist (n 5 23) or established retrospec-
tively using information obtained from the unaffected
relatives (n 5 338); a retrospective diagnosis in the
affected relative required a combination of parkinso-
nian symptoms and signs as deﬁned by the United
Kingdom Parkinson’s Disease Society Brain Bank
(UK-PDSBB) criteria,17 responsive to dopaminergic
medication; (2) absence of a history of other (neuro-
psychiatric) disorders or conditions known to inﬂuence
olfactory function; (3) no medication that might inﬂu-
ence dopamine transporter binding and/or olfactory
function; (4) absence of parkinsonism as deﬁned by
the United Kingdom Parkinson’s Disease Society Brain
Bank (UK-PDSBB) criteria17; (5) Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS) motor score <5; (6)
Cambridge examination for mental disorders (CAMCOG)
orientation and memory section score >26. All partici-
pants gave written informed consent; the protocol of
the study was approved by the Health Council of The
Netherlands and the local medical ethical committee of
the VUMC.
Baseline Testing
At baseline, all 361 subjects were submitted to a
combination of three olfactory processing tasks and
two executive function tasks known to be disturbed in
early stage PD patients. The olfactory tests included an
odor detection, an odor discrimination and an odor
identiﬁcation task.5 The odor detection task was
adapted from a task developed by Doty et al.18 The
odor discrimination task used was developed at the
University Medical Center Utrecht.19 A modiﬁed ver-
sion of the 12-item Cross-Cultural Smell Identiﬁcation
Test (CC-SIT),20 adapted to the Dutch population, was
used to assess odor identiﬁcation.
The ﬁrst executive function task was the Vienna per-
severation task (Dr. G. Shuhfried Ges.m.b.H, Mo¨dling,
Austria) in which perseveration in the generation of
random motor behavior is examined.13 The second task
was the Vienna adaptation of the Corsi Block-Tapping
Task (Dr. G. Shuhfried Ges.m.b.H, Mo¨dling, Austria)
used to assess sequential visuo-spatial memory span.12
Five Year Follow-Up
Five years after baseline testing, 354 subjects were
available for follow-up. Seven relatives were lost to
follow-up, six of whom died. For one relative, we
were unable to trace his current address. A subgroup
of seventy-four relatives was selected at baseline for
additional dopamine transporter SPECT scanning as
part of the follow-up evaluations.5 This selected group
was seen at the outpatient clinic for movement disor-
ders of the VUMC and subjected to a full clinical neu-
rological examination. Follow-up of the majority of
relatives (n 5 280) was performed by means of a mail
questionnaire sensitive to the presence of Parkinsonism
(see below). Eighteen relatives with possible Parkin-
sonism according to the questionnaire were subse-
quently invited to the outpatient clinic for a full neuro-
logical evaluation.
Clinical neurological examinations were carried out
by a movement disorders specialist and included a
screening neurological examination and a speciﬁc
assessment to detect the presence of Parkinsonism as
deﬁned by the UK-PDSBB criteria.17 Motor function
was rated by means of the motor section of the
UPDRS. Individuals that had already developed clini-
cal PD prior to the scheduled 5 year follow-up evalua-
tion and were already using medication were tested
‘‘off’’-medication, i.e. at least 12 hours after their
evening dose.
The mail questionnaire used was a Dutch translation
of a validated screening questionnaire for PD, as
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described previously.6 This mail questionnaire com-
prised nine symptom questions and an extra question
to establish whether any physician had made a diagno-
sis of PD over the course of the follow-up period.
Three or more positive responses to the symptom ques-
tions, as well as a positive response to the additional
question, were considered indicative of possible Par-
kinsonism. Individuals with possible Parkinsonism
according to the questionnaire were submitted to a
structured clinical work-up, comprising a standard his-
tory taking and a neurological examination including
the UPDRS motor score. The structured clinical work-
up was performed by a movement disorders specialist,
who was not involved in the baseline screening and
was blinded to the baseline olfactory and executive
function test scores.
The data were analyzed in SPSS (SPSS inc., Chi-
cago, IL, U.S.A.). Cox-regression analysis (univariate
and multiple) was used to calculate hazard ratios for
developing PD. The relation with olfactory and execu-
tive function subscores was analyzed using a forward
stepwise method (0.05 probability of F for entry, 0.10
for removal of a determinant from the regression equa-
tion) using three olfactory function subscores (odor
detection, odor discrimination, odor identiﬁcation), two
executive function subscores (visuo-spatial memory
span, perseveration) as well as age and sex in the ini-
tial regression equation.
RESULTS
Five years from baseline testing, ﬁve relatives had
developed clinical PD as deﬁned by the UK-PDSBB
criteria. Initial clinical (motor) symptoms appeared 9
to 52 months (median 15 months) after baseline test-
ing. Five years from baseline, ‘‘off’’-medication
UPDRS motor scores were 13, 16, 18, 29, and 52.
Three relatives were using antiparkinsonian medication
(dopamine-agonist and/or levodopa), and had a good
clinical response. Of the other 349 relatives available
for follow-up, none fulﬁlled UK-PDSBB criteria for
a parkinsonian syndrome. This included the relatives
in the questionnaire group, 18 of whom had 3 to 7
(out of nine) positive responses to the screening
questionnaire. Clinical neurological evaluation did
not reveal a parkinsonian syndrome in any of these 18
relatives.
The olfactory processing task scores in the ﬁve rela-
tives that had developed PD were signiﬁcantly lower
than in the healthy subjects. No signiﬁcant difference
between groups was found for the scores on the execu-
tive function tasks. Mean 6 SDs for olfactory and ex-
ecutive function testing are listed in Table 1.
Univariate Cox regression analysis of the test scores
on the individual olfactory processing tasks revealed a
signiﬁcantly increased risk of developing PD with
lower scores for each task (Table 2). The hazard ratio
for odor discrimation was 0.73, which indicates that
when the odor discrimination score decreases with one
point, the risk of developing PD increases with 0.73.
The hazard ratios for odor detection testing and odor
identiﬁcation testing were 0.60 and 0.62, respectively.
When the individual olfactory processing tasks were
combined into a multiple Cox-regression analysis, the
odor discrimination task was the best predictor for
future PD. The contribution of the odor detection task
was limited (trend), whereas the baseline score on the
odor identiﬁcation task did not have any additional
value in predicting the future development of PD. Per-
formance on the two executive function tasks was not
associated with the risk of developing clinical PD.
TABLE 1. Demographics and scores on olfactory
processing tasks and cognitive tasks (mean 6 SD),
measured at baseline
PD (n 5 5)
No PD
(n 5 348)
Lost to
follow-up (n 5 8)
Sex (male / female) 3/2 150/198 4/4
Age (mean 6 SD) 62.4 6 6.3 58.7 6 6.5 58.6 6 8.1
Odor discrimination 13.6 6 4.8 21.0 6 4.4 20.8 6 3.7
Odor detection 9.8 6 1.3 13.3 6 2.1 14.4 6 1.2
Odor identiﬁcation 7.2 6 2.1 9.7 6 1.7 10.6 6 0.9
Corsi block task 5.6 6 0.9 5.3 6 0.9 5.5 6 1.3
Perseveration task 23.6 6 8.4 23.2 6 10.1 18.9 6 7.2
TABLE 2. Cox regression analysis
Univariate Multivariate
Hazard ratio (c.i.) P Hazard ratio (c.i.) P
Odor discrimination 0.728 (0.606–0.875) 0.001 0.810 (0.665–0.986) 0.036
Odor detection 0.598 (0.436–0.819) 0.001 0.724 (0.501–1.045) 0.084
Odor identiﬁcation 0.622 (0.463–0.835) 0.002 – –
Corsi block task 1.357 (0.584–3.151) 0.477 – –
Perseveration task 1.005 (0.926–1.090) 0.912 – –
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DISCUSSION
In this prospective study involving ﬁrst-degree rela-
tives of PD patients, worse performance on each of
three olfactory processing tasks was associated with an
increased risk of developing PD within 5 years.
Among the olfactory tests used, odor discrimination
testing appeared to be the best predictor for the future
development of PD. Baseline executive function, as
measured using two tasks known to be impaired in
early-stage PD patients,12–14 did not have any predictive
value for a later diagnosis of PD in this population.
The ﬁrst indications that an impaired sense of smell
might be taken as an early sign of the development of
PD were derived from two studies observing olfactory
dysfunction in asymptomatic relatives of patients with
either familial or sporadic forms of PD.21,22 Subse-
quently, the baseline evaluation of the present cohort
of ﬁrst degree relatives of PD patients revealed a sub-
clinical degeneration of the nigrostriatal dopaminergic
system in some hyposmic, but otherwise asymptomatic,
ﬁrst-degree relatives of PD patients.5 Two-year follow-
up data of this same cohort showed that unexplained
olfactory loss can indeed be a ﬁrst sign of PD.6 This
notion was later conﬁrmed in an independent study in
individuals with idiopathic hyposmia.8 Recently, the
above observations in selected populations were corro-
borated in a population-based study of elderly men
using a short test of odor identiﬁcation.9,23 The present
ﬁve-year follow-up data of our cohort of ﬁrst-degree
relatives of PD patients, conﬁrm the increased risk of
future PD conveyed by olfactory loss over a ﬁve-year
period and, in addition, show that odor discrimination
testing may be the better test to use.
The recently published data from the Honolulu-Asia
Aging Study9 have shown that impaired olfaction was
not a strong predictor of PD when follow-up time from
olfactory testing to the development of PD was beyond
4 years. This might imply that olfactory deﬁcits in PD
begin 4 years or less before the appearance of classic
motor features. This notion is supported by the obser-
vation by Marras et al.24 in a population of twins that
impaired olfaction was not a good indicator of future
PD more than 7 years prior to the development of the
typical motor signs. In the present ﬁve-year follow-up
study the longest interval between baseline olfactory
testing and the development of clinical PD was 52
months (4.3 years). Similar results were found by
Haehner et al.8 However, follow-up data beyond a
5 year period are necessary before ﬁrm conclusions
can be made about the length of the pre-motor period
characterized by hyposmia.
Previously, Doty et al.25 and Lotsch et al.10 have
reported that olfactory test scores on different tasks
(identiﬁcation, discrimination, and detection) load on
a single primary component in a principle component
analysis. Apparently, the available olfactory tests
share a certain aspect of olfactory function. Yet, this
does not imply that odor detection, identiﬁcation, and
discrimination are fully equivalent olfactory modal-
ities. The results of the present study would seem to
support that different olfactory tasks may tap into
different cerebral functions. Several imaging studies
provide additional anatomical evidence for this con-
cept, demonstrating that olfactory functions are medi-
ated by common as well as task-speciﬁc regions in
the brain.26,27
Neuropsychological investigations in PD patients
have shown speciﬁc executive impairments in the ini-
tial phase of the disease.12,13 It is therefore tempting to
speculate that executive function deﬁcits may also
occur in the pre-motor stage of PD, a notion supported
by the observation in the MPTP monkey that executive
function deﬁcits are present before the onset of clinical
motor disturbances.15,16 In the present study, baseline
executive function in asymptomatic ﬁrst-degree rela-
tives of PD patients was not associated with the risk of
developing PD within 5 years. This would seem to
argue against the presence of executive impairments in
the pre-motor stage of PD and, in addition, imply that
tasks of executive function are not helpful in the pre-
clinical diagnosis of PD. However, it should be empha-
sized that we used only two speciﬁc tasks involving
executive functions. Therefore, we can not exclude
that other tests of (executive) cognitive function might
serve better as predictors for the development of
future PD.
The present results support the existing evidence
that olfactory processing tasks might be useful as part
of early diagnostic strategies in PD. Among the olfac-
tory tests used, the odor discrimination test appeared to
be the best predictor of future PD. This is somewhat
unexpected since in previous studies, including a recent
study comparing odor identiﬁcation and odor discrimi-
nation deﬁcits in PD patients, we found impaired odor
identiﬁcation performance to be more prevalent than a
deﬁcit in odor discrimination.3,28 Moreover, odor iden-
tiﬁcation testing differentiated better between PD
patients and healthy subjects than odor discrimination.
In the latter study, contrary to the present study, ele-
ments of the Snifﬁn’ Sticks test battery were used,
including a 16 item discrimination task. In the present
study, the discrimination task comprised 32 items.
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Therefore, differences in the olfactory tasks used as well
as the different number of items in the discrimination
task might have contributed to the apparently contra-
dictory results. Clearly, the exact value of the individ-
ual aspects of olfactory function in predicting future
PD needs further study.
A limitation of this study is that we used a selected
sample of relatives of PD patients, excluding subjects
with a history of other disorders or conditions known
to inﬂuence olfactory function. Therefore, our results
are not necessarily applicable to the general popula-
tion. In addition, only ﬁve individuals of 361 ﬁrst
degree relatives of PD patients developed clinical PD
during our prospective study. Although this number of
cases corresponds to the expected incidence of new
cases over the 5 year follow-up in a cohort of this size,
a larger baseline population and hence a higher number
of PD patients would provide a more accurate predic-
tive value for olfactory and executive function testing.
Another limitation is that we tested only two speciﬁc
aspects of executive function; i.e. motor perseveration
and sequential visuo-spatial memory span. It could
well be that other tasks measuring similar or different
aspects of executive function have better predictive
value for the development of PD. On the other hand,
early stage PD patients were impaired on these particu-
lar tasks in previous studies.12,13
An important strength of this study is its prospec-
tive, longitudinal design. Furthermore, in spite of the
long interval between baseline evaluation and ﬁve-
year follow-up, only very few individuals were lost to
follow-up.
In conclusion, we found that in a cohort of ﬁrst-
degree relatives of PD patients worse performance on
each of three olfactory processing tasks was associated
with an increased risk of developing PD within 5
years, whereas executive dysfunction was not associ-
ated with an increased risk of developing PD within 5
years. Impaired odor discrimination appeared to be the
best predictor of the future development of PD.
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